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A monoclonal antibody specific for mouse dendritic cells
M. C. NUSSENZWEIG, R. M. STEINMAN, M. D. WITMER, AND B. GUTCHINOV
Department of Cellular Physiology and Immunology, The Rockefeller University, New York, New York 10021
Communicated by Zanvil A. Cohn, September 8, 1981
ABSTRACT Dendritic cells (DC) are a small subpopulation
of lymphoid cells with distinctive cytologic features, surface prop-
erties, and functions. This report describes the DC-specific an-
tibody (Ab) secreted by clone 33D1. Rat spleen cells immune to
mouse DC were fused to the P3U myeloma. Hybrid culture su-
pernatants were screened simultaneously against DC, a macro-
phage (M40) cell line, and mitogen-stimulated lymphoblasts. 33Di
Ab specifically killed 80-90% ofDC from spleen and lymph node,
but no other leukocytes, including Ia+ and la- MC (Ia, I-region-
associated antigen). Quantitative binding studies with 3H-labeled
33D1 Ab showed that DC had an average of 14,000 binding sites
per cell. Binding to DC was inhibited with Fab fragment of 33D1
Ab but not with a panel of other monoclonal antibodies, including
anti-Ia Ab. Adherence and flotation procedures that enriched for
DC enriched for 3H-labeled 33D1 Ab binding in parallel. 33D1
antigen was not detectable on: MCI from spleen, peritoneal cavity,
and blood; three M(I cell lines; lymphocytes; granulocytes; plate-
lets; and erythroid cells. DC continued to express the 33DI antigen
after 4 days in culture, whereas MI and lymphocytes did not ac-
quire it. Quantitative and autoradiographic studies confirmed that
spleen and lymph node suspensions contain less than 1% DC. We
conclude that 33D1 Ab detects a stable and specific DC antigen
and can be used to monitor DC content in complex lymphoid
mixtures.
Dendritic cells (DC) are morphologically distinct cells discov-
ered in adherent populations from mouse lymphoid organs (1).
DC can be highly enriched on the basis oflow buoyant density,
adherence to glass or plastic, and lack of Fc fragment receptors
(2). DC express abundant I-region-associated antigen (Ia Ag)
and lack the characteristic surface markers of B cells, T cells,
macrophages (MF), and granulocytes (refs. 3 and 4, reviewed
in ref. 5). DC are also functionally distinct. For example, DC
are 100-fold more effective than other leukocytes in stimulating
allogeneic and syngeneic mixed leukocyte reactions (6, 7) and
function as potent accessory cells during the generation of cy-
totoxic lymphocytes (8) and oxidative mitogenesis (9, 10).
A DC-specific antibody (Ab) would be a valuable probe for
further in vitro and in vivo studies. Attempts to generate such
a reagent by injecting mouse DC into rabbits failed*because the
principal reactivity was directed to Ia and H-2 Ag (unpublished
data). In this communication, we have used hybridoma tech-
nology to generate the DC-specific Ab, clone 33D1. Specificity
was monitored by cytotoxicity assays as well as quantitative
binding and autoradiographic studies with radiolabeled Ab.
Expression of the 33D1 Ag in mouse lymphoid suspensions
precisely paralleled the distribution of DC as previously as-
sessed by cytologic (1-3) and functional (6) assays.
MATERIALS AND METHODS
Animals. (DBA/2 X BALB/c) FI/Tru, (A x C57BL/6) F1/
Tru, C57BL/6 Tru, (BALB/c X C57BL/6) FI/Tru, and C3H/
J, C3H. OH/J, and Swiss mice were obtained from the Trudeau
Institute (Saranac Lake, NY), The Jackson Laboratory, Taconic
Farms (Germantown, NY), and The Rockefeller University
(New York). Sprague female rats were from Charles River
Breeding Laboratories.
Antibodies. Rabbit antiserum to rat Ig (Cappel Laboratories,
Cochranville, PA) was affinity purified on Sepharose-rat-Ig and
digested to F(ab')2 fragments as described (4). Rabbit antiserum
to mouse Ig was from Cappel Laboratories. A number ofmono-
clonal antibodies of defined specificity (4) were employed: B21-
2 and 2E8 are anti-I-A reagents; B25-1 is anti-H-2D; 2.4G2
identifies the Fcyreceptor; B5-3 is anti-Thy-i; 1.21 J reacts with
the "mac-l" Ag on Mb and granulocytes; and 2.D2C and 2.6
react with Ag found on DC as well as other cell types.
Cells. Suspensions of spleen, lymph node, and thymus were
prepared by teasing and disruption on a stainless steel sieve.
Bone marrow was flushed from femurs, peritoneal cells were
harvested from the abdominal cavity, and blood mononuclear
leukocytes were separated on dense Ficoll/Hypaque. DC were
purified from spleen and lymph node by a four-step procedure
that involved: flotation on dense albumin columns, adherence
to glass or plastic, overnight culture (during which DC lose the
capacity to adhere), and removal of MI by rosette formation
with Ab-coated erythrocytes (EA) or readherence as described
(2, 7). MW were purified from spleen, node, peripheral blood,
and peritoneal cavity by adherence (4). The J774, P388D1, and
RA264.7 M4 cell lines were the gift of J. Unkeless and were
maintained in a modified minimal essential medium containing
10% fetal calf serum.
Preparation of Hybridoma Ab. A 300- to 400-g rat was im-
munized with 3 x 106 DC in complete Freund's adjuvant sub-
cutaneously in the footpads and~back. The rat was boosted in-
travenously with 3 x 106 DC on days 30, 60, and 90. Immune
spleen cells were fused with the mouse myeloma line P3U-1 at
a ratio of 4:1 three days after the last DC boost, according to
the method of Kohler and Milstein (11). Supernatants were as-
sayed by using an indirect binding assay on low-density spleen
adherent cells [LODAC, a mixture ofDC and MWI (2)], the J774
MF cell line, and phytohemagglutinin-stimulated lymphoblasts
(12). ..T lymphoblasts, which are rich in Ia, were required to
detect clones secreting anti-Ia antibodies. Test cells (104) were
attached to Terasaki dishes (Falcon Plastics, Cockeysville, MD)
coated with poly(L-lysine) [poly(L-Lys), 50 ,ug/ml; Sigma] and
Abbreviations: DC, dendritic cell(s); M4, macrophage(s); Ag, antigen;
Ia, I-region-associated Ag; Ab, antibody; EA, erythrocytes coated with
Ab; C, complement; LODAC, low-density adherent cells.
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then exposed sequentially to hybridoma supernatants and 125I-
labeled F(ab')2 anti-rat Ig at 10 jig/ml and 10-20 ,ACi/tig (1 Ci
= 3.7 X 1010 becquerels). Supernatants binding preferentially,
to DC were identified by autoradiography with Kodak XR-l film
exposed at -70°C for 12-24 hr with image intensifier screens
(Lightning Plus, Du Pont). Selected hybridomas were then
cloned on agar and ascites was produced by injecting 5-10 x
106 cells into mice primed with pristane (Aldrich) and irradiated
[600 rads (6 grays)].
Purification, Digestion, and Radiolabeling of33D1 Ab. The
DC-specific and cytotoxic reagent 33D1 was purified from as-
cites by two precipitations with 45% saturated ammonium sul-
fate followed by chromatography on DEAE-cellulose (DE-52,
Whatman) developed with 0.0175 M sodium phosphate, pH
6.3. Fab fragments were obtained by digestion with 1% papain
(Sigma) in 0.1 M sodium acetate (pH 5.5)/10 mM 2-mercap-
toethanol/1 mM EDTA for 12 hr at 37°C. The digestion was
monitored by sodium dodecyl sulfate/polyacrylamide gel elec-
trophoresis under reducing conditions (Fig. 1). 33D1 was la-
beled with boro[3H]hydride (New England Nuclear) by reduc-
tive methylation to a level of 2-5 ,uCi/,ug exactly as described
by Tack et al. (13). The 33D 1 Ab was inactivated ifradioiodinated
by chloramine-T, IODO-GEN, lactoperoxidase and glucose
oxidase, or Bolton-Hunter procedures under conditions in
which other monoclonal antibodies were successfully labeled
(4). An anti-Ia Ab, 2E8, was also tritiated, although a much
lower specific activity (0.1 ,uCi/,ug) was sufficient.
Cytotoxicity Assays. All cytotoxicity assays were performed
with excess Ab (saturating concentration for 33Dl-mediated
killing was 1-2 ,ug/ml). Cells at 5-10 x 106 per ml were mixed
with equal volumes ofAb and rabbit complement (C) (absorbed
with agarose, 80 mg/ml) for 60 min at 37°C. Cytotoxicity in sus-
pension was assessed by trypan blue exclusion. Killing of DC
or MFD on adherent monolayers was monitored as described in
the text.
Quantitative Binding Studies with Radiolabeled Ab. La-
beled Ab was added on ice for 60 min to cells in suspension,
adherent to tissue culture surfaces, or attached to 16-mm wells
coated with poly(L-Lys). Unless otherwise stated, the binding
mixtures contained saturating concentrations of labeled Ab, 5%
Intact Fab
FIG. 1 Sodium dodecyl sulfate/5-11% polyacrylamide gel electro-
phoresis of purified 33D1 Ab before (Intact) and after (Fab) digestion
with papain. The 33D1 Ig has a heavy chain with a molecular weight
of 56,000, presumably an IgG, and two light chains, presumably one
each from the rat spleen and mouse myeloma parents. The heavy chain
is digested with papain.
10 15
33D1, yg/ml
FIG. 2. Two experiments in which different concentrations of 3H-
33D1 and unlabeled 33D1 were added to 1.2 X 106 C3H (x) or 1.9 x
105 Swiss (0) spleen DC. Saturable binding was demonstrable.
newborn calf serum, 0.02% sodium azide, and saturating levels
of nonlabeled 2.4G2 anti-Fe receptor Ab to block Fc-mediated
binding (14). After 60 min, the cells were rapidly washed (2-5
min) and then lysed in 0.1 M NaOH, and radioactivity was
measured by using Hydrofluor (National Diagnostics, Somer-
ville, NJ) as scintillant. Bound 3H-labeled 33D1 (3H-33D1) dis-
sociated from DC slowly (10-15% per 15 min). The amount of
binding to cells in suspension was identical to that bound by
cells attached to poly(L-Lys). Background binding (100-350
cpm per assay) was determined by omitting cells or blocking
with a 20- to 30-fold excess of unlabeled Ab.
Binding assays were also used to quantitate the Mb and Ia
content of adherent cell preparations. 125I-Labeled 1.21J (anti-
mac-i) and "2I-labeled B21-2 (anti-I-Ab d) were used as de-
scribed (4);
Autoradiography. 3H-33D1 was applied to cells adherent, or
attached [poly(L-Lys)], to coverslips as in quantitative binding
assays. Coverslips were washed, blow dried, fixed in methanol,
attached to slides, dipped in Ilford L4 emulsion (Polysciences,
Warrington, PA) diluted 1:3 in water, and exposed 10-20 days
prior to development in D19 (Eastman).
Table 1. Specificity of 3H-33D1 binding
Blocking antibody: 3H-33D1bound,cpm
Clone and specificity Exp. A Exp. B
None 1707 NT
33D1, intact Ig, aDC 49 -40
33D1, Fab fragment 149 142
2E8, aI-A 1521 942
B21-2, aI-A 1638 903
B25-1, aH-2D 1660 921
2.4G2, aFcy 1633 882
2.6, aDC + other cells NT 981
2.D2C, aDC + other cells NT 934
SpleenLODAC (2 x 106) were prepared from (DBA x BALB/c) (Exp.
A) and Swiss (Exp. B) mice. Cells were exposed to a group of unlabeled
monoclonal antibodies whose specificities have been described (4) for
60 min on ice. Then 3H-33D1 was added at a final concentration of 3.5
Ag/ml for another 60 min. Binding is expressed ascpmbound with cells
minus cpm bound without cells ("300 cpm) for duplicate cultures. In
Exp. B,. all cultures were supplemented with saturating levels of un-
labeled 2.4G2 in addition to the other Ab. NT, not tested; a, anti-.
Proc. Natl. Acad. Sci. USA 79 (1982)
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Table 2. 3H-33D1 binding to lymphoid DC and Mb
Test 3H-Labeled Ab bound, cpm
population Exp. A (Swiss) Exp. B (C3H)
(2 x 105
cells) 33D1 (aDC) 2E8 (al-A) 33D1 (aDO) 2E8 (al-A)
No cells 5 -12 5 -6
Spleen DC 1626 3657 1283 1527
Node DC 1640 3164 1189 1695
Spleen MbD 75 520 55 958
Spleen MV 75 230 -11 730
Node Mb' 240 1570 -8 216
Mb were purified from LODAC (7) or from high-density cells (*) (4)
as described. In both techniques the MO were exposed to the same al-
bumin columns used to purify DC. 3H-Labeled Ab bound refers to cpm
binding blocked by a 30-fold excess of unlabeled Ab; this is similar to
cpm bound with cells minus cpm bound without cells.
RESULTS
To select for DC-specific Ab, hybridoma culture supernatants
were screened against LODAC, the J774 MWD cell line, and
phytohemagglutinin-induced lymphoblasts, using an 1"I-la-
beled F(ab')2 anti-Ig binding assay. Supernatants that selec-
tively bound to LODAC were then tested for cytolytic activity
in the presence of rabbit C. 33D1 was the only supernatant that
was cytotoxic, killing 30-80% of cultured LODAC from all
mouse strains (see Materials and Methods). Therefore the cells
in this culture were cloned on soft agar and specificity for DC
was established with quantitative binding, autoradiographic,
and cytotoxicity assays.
Quantitative Binding Studies. Binding studies with radio-
labeled primary Ab provide a sensitive means of quantitating
specific antigens on small numbers of test cells (4). 33D1 bind-
ing to spleen DC saturated at 15 ,ug/ml, corresponding to 1.4
X 104 binding sites per DC (Fig. 2). By Scatchard analysis, the
association constant was -4 X 10-7 M-1. The specificity of
binding to DC was tested by blocking with unlabeled mono-
clonal Ab (Table 1). Both intact Ab and Fab fragments of 33D1
inhibited binding. A number of other monoclonal antibodies
that react with DC, including anti-I-A reagents, did not com-
pete with 3H-33D1. Thus 3H-33D1 binding to DC is saturable,
is not Fc mediated, and identifies a novel DC determinant. All
subsequent studies on the tissue distribution of33D1 were per-
formed with a dose of 3.5 ,g/ml (60% saturation), because
higher concentrations produced high levels of dish binding and
were prohibitively expensive.
Table 3. 3H-33D1 binding to mouse leukocytes
3H-Labeled Ab bound, cpm
Test population 33D1 (aDC) 2E8 (aI-A)
Adherent to plastic
No cells 7 4
Peritoneal M4, 3 x 105 -87 486
Blood monocytes, 3 x 105 13 102
Spleen M4, 3 x 105 186 363
Attached to poly(L-Lys)
No cells -15 20
Spleen DC, 3 x 105 3313 3905
Spleen, 6 x 106 684 2186
Node, 6 x 106 185 2981
Thymus, 6 x 106 31 540
Marrow, 6 x 106 133 490
Nonadherent peritoneal, 4 x 106 43 2269
Nonadherent blood, 4 x 106 5 1232
Blood platelets 14 244
Table 4. Enrichment of 3H-33D1 binding after flotation
and adherence
3H-Labeled monoclonal Ab bound, cpm
Spleen Lymph node
Test 33D1 2E8 33D1 2E8
population (aDO) (al-A) (aDO) (aI-A)
Unfractionated,
6 x 106 255 3039 240 1618
High-density,
6 x 106 86 2060 96 1338
LODAC,
3 x 105 1220 1606 2123 1699
Low-density
nonadherent,
4 x 106 623 3026 244 2669
Spleen and lymph node from Swiss mice were separated into three
subpopulations on the basis of buoyant density and plastic adherence
(2, 3). Data are expressed as cpm blocked with a 20-fold excess of spe-
cific unlabeled Ab. The low-density fraction represented 5% of total
spleen and 12% of total lymph node.
Binding of 3H-33D1 was first tested on DC and MC) from
several organs. DC from spleen and lymph node bound similar
levels ofAb (Table 2). MCI from spleen, lymph node, peritoneal
cavity, and blood (Tables 2 and 3) showed little or no binding,
even when larger numbers of cells (2 x 106 spleen or peritoneal
MCI) were tested and even when MCI expressed considerable
levels of Ia Ag. In some experiments, low levels of 3H-33D1
(about 1000 molecules per cell) bound to MCI-rich preparations.
This could be attributed to small numbers ofDC contaminating
these populations, to Fc-mediated binding (i.e., binding not
inhibitable by 33D1 Fab), or to both. Three MI cell lines-J774,
P388D1, and Ra 264.7-also lacked the 33D1 Ag (not shown).
Cells from six different tissues were screened next. Sensitiv-
ity was enhanced by using large numbers of test cells (4-6 X
106). Specific 3H-33D1 binding was detectable in spleen and
corresponded to a level of 1 DC per 100-300 splenocytes. Bind-
ing above background was noted in lymph node, but was weak
or absent in suspensions from thymus, peritoneal cavity, blood,
and bone marrow (Table 3). Binding of'H-labeled 2E8, an anti-
Ia reagent used as a positive control, was detectable in all prep-
arations and did not correlate with the level of 33D1 Ag.
Spleen and lymph nodes were then fractionated by buoyant
density and plastic adherences to prepare populations enriched
in or depleted of DC by cytologic (3) and functional (6) assays.
3H-33D1 binding correlated with DC content (Table 4). Specific
binding was enriched 8- to 10-fold in the DC-rich low-density
fraction. Ofthe binding in the low density fraction, 65-90% was
in the adherent component. The latter represents less than 10%
of the low-density cells and usually contains 75% or more of the
DC.
Spleen DC, MO, and lymphocytes were tested after 4 days
ofculture. The level of33D1 binding per DC fell approximately
50% (Table 5). MI and lymphocytes did not acquire the Ag
Table 5. Expression of 33D1 at various times in culture
Time in culture, hr 33D1 bound per 105 DC, ng
1-3 0.215 ± 0.050 (3)
18-26 0.164 ± 0.033 (9)
80-90 0.101 + 0.026 (3)
Spleen LODAC were cultured for 1-90 hr and the percent DC was
monitored by cytologic criteria (1, 2). Binding of 33D1 is expressed as
ng of 3H-33D1 bound (specific activity 4 x 106 cpm/ng), mean ± SD,
with number of experiments in parentheses.
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FIG. 3. Phase-contrast micrographs of lymph node LODAC ob-
tained on albumin columns. Equal volumes of cells (107 per ml), Ab,
and C were mixed and cultured for 1 hr at 37°C. Viable adherent cells
attached firmly, nonadherent cells were removed, some of the prepa-
rations were fixed in 1.25% glutaraldehyde (A andB), and others were
challenged with EA for 1 hr prior to fixation (C and D). (A) Adherent
cells exposed to C without Ab. The field contains two typical DC, with
many phase-dense mitochondria, and two ruffled round MC. (x340.)
(B) Adherent cells prepared in the presence of 33D1 + C. DC have been
killed but four typical MO can be seen. Cell counts of the entire cov-
erslip show that DC numbers are reduced 80-90% while MI numbers
are unchanged after exposure to 33D1 + C. (x 280.) (C) Same asA, but
fed EA. Four MC in the field have bound and interiorizedEA (ingested
EA are dark, and attached EA are light or refractile), while the three
DC have not. (x280.) (D) Same as B, but challenged with EA. 33D1
kills DC, leaving an adherent population consisting primarily of MO
that bind and phagocytose EA. (x280.)
(not shown). We conclude that 33D1 binding is specific for DC
and can be used to monitor DC content in complex leukocyte
mixtures.
Autoradiography. Autoradiograms were prepared from se-
lected cell populations to visualize the 33D1 Ag at the single-
cell level. Fresh and cultured spleen LODAC were 30-70%
labeled, while whole spleen adherent cells were 5-15% labeled.
Labeled cells were infrequent (<1%) in unfractionated spleen
and lymph node and in purified spleen MF.
Cytotoxicity Assay. The next series of experiments estab-
lished that DC were selectively killed by 33Di plus C. LODAC
were prepared from spleen and lymph node and exposed to C,
33D1 Ab, or both Ab and C. The latter killed 80-90% of the
cells with the cytologic features of DC (compare Fig. 3 A and
B). MFP were not killed and continued to bind and phagocytose
EA (compare Fig. 3 C and D). Specificity was further investi-
gated by separating i-day-cultured LODAC into DC- and MCF-
rich fractions by EA rosetting (2). Of the DC-enriched, EA-
fraction, 80-90% from both spleen and node were killed (Table
6). Only 0-10% of the M(I-rich, EA+ fraction were killed, and
Table 7. 33D1 + C fails to kill most mouse leukocytes
Cells killed, %
Ab (clone) SpI. Thy. PC Blood BM
Exp. A (C3H)
None 4 4 4 3 3
aDC (33D1) 4 2 5 5 2
aI-Ak (10-2.16) 62 11 49 12 2
aI-Abd (B21-2) 8 3 5 5 3
ahy-i (B5-3) 39 100 36 63 3
alg serum 56 5 11 11 4
Exp. B (B6 x D2)
None 1 9 8 6 9
aDC (33D1) 4 8 7 4 10
aI-Ak (10-2.16) 4 9 7 4 11
al-Abd (B21-2) 50 16 25 19 12
aThy-1 (B5-3) 32 100 39 54 14
aIg serum 54 8 8 17 12
Cytotoxicity assays were run on leukocytes from spleen (Spl.), thy-
mus (Thy.), peritoneal cavity (PC), blood, and bone marrow (BM). An-
tibody alone produced no killing above background.
this low level could be attributed to DC, which are known to
contaminate the EA' fraction (2). 33DI-mediated killing was
not detectable either in cultured spleen or lymph node (Table
6) or in fresh unfractionated suspensions from spleen, thymus,
peritoneal cavity, blood, marrow (Table 7), and lymph node (not
shown). Controls with anti-Ig, anti-Thy-i, and anti-Ia produced
appropriate levels of killing in all test populations (Tables 6 and
7).
Quantitative binding and autoradiographic assays were de-
signed to determine whether 33D1 + C killed Ia' or Ia- M4.
After exposure to Ab + C, M4 content was monitored with 125i-
labeled 1. 21J (which binds to the mac-i Ag on MO but not DC)
and Ia was quantitated with '"I-labeled B21-2 (anti I-Ab~d).
Treatment with 33D1 + C produced no change in the level of
either 1.21J or B21-2 binding in purified M1 from blood, per-
itoneal cavity, or cultured spleen (Table 8). By autoradiography,
the percentage of Ia-bearing cells was also unchanged (Table
8). In contrast, 33D1 + C treatment of fresh spleen LODAC,
which contain substantial numbers of DC, decreased the
amount ofTa but not 1.21J (mac-i) on the monolayer. This result
indicates that the Ia-rich 1.21J-poor DC had been selectively
removed. By autoradiography the percentage of 1.21J+ cells
increased and B21-2+ cells decreased after removal ofmost DC
(Table 8). These cytotoxicity studies show that 33D1 kills DC
but not other leukocyte, including Ia+ and Ia- MF.
Table 6. 33D1 specifically kills DC in cultured spleen and lymph node
Cells killed in spleen, % Cells killed in lymph node, %
High-density High-density
Ab + C EA- EA+ (lymphocyte- EA- EA+ (ymphocyte-
treatment (DC-rich) (MCI-rich) rich) (DC-rich) (MW-rich) rich)
NoAb 2 10 7 5 14 9
aDC (33D1)
33 jg/ml 83 17 9 84 13 10
3.3,ug/ml 88 18 7 80 15 11
0.33 ,ug/ml 54 12 8 23 13 9
aThy-l (B5-3) 2 8 28 6 12 55
aI-A (B21-2) 96 65 62 88 50 45
aIg 3 6 58 3 12 38
LODAC were prepared from spleen and lymph node, cultured overnight, and separated into DC- and
MW-rich components after rosetting with EA. Cultured high-density cells were used as a lymphocyte-rich
suspension. Cytotoxicity assays were carried out with monoclonal antibodies (except for anti-Ig) and agar-
ose-adsorbed rabbit C. Killing did not occur when C was omitted.
Proc. Nad Acad. Sci. USA 79 (1982)
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Table 8. 33D1 + C does not kill Ia- or Ia' MO
No. of Mb, cpm 125I-1.21J No. of Ia' cells,
(% 1.21J+) cpm 125I-B21-2 (% B21-21
Adherent cells No Ab/C 33D1/C No Ab/C 33D1/C
Exp. A (D2 x C)F1
Cultured spleen LODAC (MV) 8,428 (97) 8,190 (98) 3,392 (26) 4409 (32)
Peritoneal cavity (Mb) 19,624 (99) 19,213 (100) 458 (13) 446 (19)
Blood mononuclears (monocytes) 9,726 (94) 10,669 (96) 568 (12) 524 (9)
Fresh spleen LODAC (Mb and DC) 4,198 (73) 4,113 (92) 13,171 (70) 5871 *(31)
Exp. B (C3H.OH)
Cultured spleen LODAC (Mb) 7,802 (98) 7,730 (98) 8,162 (58) 7402 (65)
Peritoneal cavity (M4) 13,287 (98) 14,574 (98) 3,732 (42) 3359 (38)
Blood mononuclears (monocytes) 3,722 (96) 3,427 (95) 1,737 (33) 1720 (30)
Fresh spleen LODAC (Mb and DC) 3,202 (70) 2,570 (95) 8,100 (78) 2913 *(52)
Four populations of leukocytes (1.5-3.0 x 107 per ml) were mixed with equal volumes of rabbit C with or without 33D1 Ab.
The suspension (75 dul) was applied to 12-mm coverslips in triplicate for 1 hr at 370C, allowing viable Mb and DC to adhere
firmly. Killing with 33D1 during rather than after adherence is preferable; there is less cell debris on the coverslip and less
toxicity to MF in the no Ab/C control. Nonadherent cells were removed, and the adherent cells (0.3-1.5 x 105) were exposed
to saturating levels of "2I-labeled monoclonal Ab on ice. 1.21J binds to the mac-i Ag on MO but not DC (4) whereas B21-1
recognizes an Iab,ddeterminant. After binding of "'5I-labeled Abthe radioactivities on the coverslips were determined and
mean cpm minus cpm without cells (Q200 cpm) was measured. Standard deviations were 10-20% for most triplicates. Statis-
tically significant differences between no Ab and 33D1 (t test) are shown with an *. After bound cpm had been measured, the
coverslips were processed for autoradiography. The percentage of labeled cells (>10 grains; 500 cells counted) is shown in
parentheses. A positive control showed a fall in '25I-labeled 1.21J binding after MO killing with B21-2 + C or with another
cytotoxic Ab.
DISCUSSION
Clone 33D1 recognizes a DC-specific surface Ag. Cytotoxicity
assays, quantitative binding studies, and autoradiography iden-
tified the Ag on most DC from spleen and lymph node. The
number of 33D1 Ag copies (-14,000) per DC is small; never-
theless, the assays used seem sufficiently sensitive to conclude
that the Ag is not present on either Ia+ or Ia- mononuclear
phagocytes (tissue MF or blood monocytes), lymphocytes,
granulocytes, platelets, or erythroid cells.
The 33D1 Ag provides an independent marker that distin-
guishes spleen and lymph node DC from other leukocytes, in-
cluding Ia-bearing cells. It is likely that DC represent a separate
leukocyte lineage because their distinctive cytologic, func-
tional, and surface properties, including expression of33D1, are
stable in vitro. The distribution of 33Dl-bearing cells closely
parallels the distribution of DC previously identified by cyto-
logic (1, 3) and functional (6) criteria. In spleen and lymph node,
this important cell type occurs at a very low frequency, less than
1% ofthe total cell suspension. Preparations from thymus, bone
marrow, peritoneal cavity, and blood have even fewer DC.
Expression of 33D1 also parallels DC content when various
enrichment procedures are applied to spleen and lymph node.
Both DC and 33D1 binding are enriched after adherence to
glass or plastic, flotation on dense albumin columns, and re-
moval of M(D by EA rosetting and readherence. Given the spec-
ificity of 33D1, it is now appropriate to use the Ab to monitor
the contribution ofDC in functional systems and to outline the
distribution of DC in vivo.
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